Letter to the Editor Regarding: “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”-Reference-Cited by-同舟云学术

Letter to the Editor Regarding: “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”

Published:2022-05-16 Issue: Volume: Page:
ISSN:2193-8229
Container-title:Infectious Diseases and Therapy
language:en
Short-container-title:Infect Dis Ther

Author:

Gomez Jorge A.^ORCID,Guevara Javier Nieto,Carlos Josefina C.,de Castro Joanne A.,Josue Donald Ray,Rodriguez Edwin

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40121-022-00640-w.pdf

Reference15 articles.

1. Perdrizet J, Horn EK, Nua W, Perez-Peralta J, Nailes J, Santos J, Ong-Lim A. Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) versus lower-valent alternatives in Filipino infants. Infect Dis Ther. 2021;10(4):2625–42. https://doi.org/10.1007/s40121-021-00538-z (Epub 2021 Sep 30).

2. Snedecor SJ, Strutton DR, Ciuryla V, Schwartz EJ, Botteman MF. Transmission-dynamic model to capture the indirect effects of infant vaccination with Prevnar (7-valent pneumococcal conjugate vaccine (PCV7)) in older populations. Vaccine. 2009;27(34):4694–703. https://doi.org/10.1016/j.vaccine.2009.05.062 (Epub 2009 Jun 9).

3. Sings HL, De Wals P, Gessner BD, Isturiz R, Laferriere C, McLaughlin JM, Pelton S, Schmitt HJ, Suaya JA, Jodar L. Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive disease caused by serotype 3 in children: a systematic review and meta-analysis of observational studies. Clin Infect Dis. 2019;68(12):2135–43. https://doi.org/10.1093/cid/ciy920 (Erratum in: Clin Infect Dis. 2021 May 4;72(9):1684–1685).

4. Palmu AA, Rinta-Kokko H, Nohynek H, Nuorti JP, Kilpi TM, Jokinen J. Impact of ten-valent pneumococcal conjugate vaccine on pneumonia in Finnish children in a nation-wide population-based study. PLoS ONE. 2017;12(3): e0172690. https://doi.org/10.1371/journal.pone.0172690.

5. Carrasquilla G, Porras-Ramírez A, Martinez S, DeAntonio R, Devadiga R, Talarico C, Caceres DC, Castrejon MM, Juliao P. Trends in all-cause pneumonia and otitis media in children aged <2 years following pneumococcal conjugate vaccine introduction in Colombia. Hum Vaccin Immunother. 2021;17(4):1173–80. https://doi.org/10.1080/21645515.2020.1805990 (Epub 2020 Sep 23).